evaluating the transporter protein inhibitor probenecid in patients with epilepsy

Conditions: Epilepsy

Summary: the study is being done to understand why some patients with epilepsy (disease of recurrence of seizures) do not respond very well to drug treatment with anticonvulsants. despite the availability of many anticonvulsants, about 30% of patients with epilepsy are resistant to them. the cause of the resistance is not clear, but one of the reasons could be an increased amount of proteins in the cells of the body called transporter proteins. transporter proteins are a group of proteins that help to defend the body against toxins, including drugs, by pumping them out of the cells. studies have shown that the number of transporter proteins is higher in the parts of the brain that trigger seizures when compared to other parts of the brain. studies in animals have shown that taking an anticonvulsant with an inhibitor (meaning "to stop" or "to reduce") of a transporter protein can increase the concentration of that anticonvulsant inside the brain cells. the main purpose of the study is to determine if taking an anticonvulsant and a transporter protein inhibitor will change the brain concentration of the anticonvulsant. in this study, a single dose of phenytoin (dilantin® is a brand name anticonvulsant which has phenytoin as its active ingredient), a commonly used anticonvulsant, will be given once by itself, and then will be given a separate time with a single (i.e. one time only) dose of probenecid. probenecid, a medicine used commonly to treat gout (a disease of increased uric acid), is known to be an inhibitor of transporter proteins. the study will use electroencephalogram or eeg (recording of brain wave activities) to determine if the eeg pattern when probenecid is given, will be different from the eeg pattern when phenytoin is given alone. this will suggest that probenecid has affected the brain concentration of phenytoin.

about 30% of patients with epilepsy are refractory to medical treatment (pharmacoresistant epilepsy). the cause of which is multifactorial. multidrug resistance (mdr) causes decreased uptake of medicines in tissues. mdr occurs because of overexpression of a family of transporter proteins that act as a physiological defense mechanism that pumps toxins out of cells. two groups of transporters, p-glycoprotein (pgp) and multidrug resistance-associated proteins (mrp), are important gatekeepers in the blood brain barrier. pgp and mrp are overexpressed in the brain tissue of pharmacoresistant patients with partial epilepsy and many antiepileptic drugs (aeds) are substrates for pgp, mrp or both. it is logical to try to apply these observations to clinical practice. we hope that through co-administration of an inhibitor of transporter proteins, we can increase the cns concentrations of aeds, and subsequently improve seizure control. however, before this, it is critical to demonstrate that a transporter protein inhibitor can increase the concentration of aeds in human brain. probenecid is an mrp inhibitor while phenytoin is an mrp substrate. evaluating whether probenecid can increase the cns concentration of pht can potentially be achieved noninvasively by using pharmaco-eeg. we plan to estimate the effect of probenecid (a transporter protein inhibitor) on the quantitative eeg recordings when it is administered to patients with pharmacoresistant epilepsy and in normal healthy volunteers. we plan to recruit two groups of 10 subjects each, normal volunteers and patients with pharmacoresistant epilepsy. they will undergo two treatment regimens; eeg recording after administration of intravenous phenytoin only and again after pre-dosing them with probenecid.

Eligibility criteria:
inclusion criteria: * men with pharmacoresistant partial epilepsy defined as failure of two or more aeds at a reasonable therapeutic dose * patient is able to understand and sign a consent form and able to keep a seizure calendar * patient is older than 18 years of age * patient is otherwise healthy by laboratory and physical examination exclusion criteria: * patient is currently taking phenytoin * patient has a history of an adverse reaction to phenytoin * patient has a history of gout disease, peptic ulcer disease, blood dyscrasias, or uric acid kidney stones * patient has an allergy to sulfa drugs or probenecid * patient has been exposed to probenecid or another known transporter inhibitor (verapamil, progesterone, etc) in the three months prior to enrollment * patient has a history of renal impairment (creatinine clearance \< 50 ml/min) * patient has a history of diabetes and is taking oral sulfonylurea agents

Keywords: pharmacoresistance healthy volunteers